November 13, 2014 | Teva Pharmaceutical Industries‘ multiple sclerosis treatment Copaxone is progressing through regulatory stages in Japan. According to estimates, the annual market potential for Copaxone in Japan is between $700-900 million. Teva signed an agreement with Japanese pharmaceutical company Takeda Pharmaceutical at the end of 2013, and while Teva believed that approval would be achieved within a year from that time, regulatory approval has yet to be granted. According to most estimates, the Copaxone drug is responsible for more than half of Teva’s profits.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli Startup Rings Closing Bell At Nasdaq in NYC
March 28, 2024
Israeli, US Companies Unite To Make More Milk From Mushrooms
March 27, 2024
Facebook comments